Literature DB >> 19839063

Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation.

José A Carrión1, Ferran Torres, Gonzalo Crespo, Rosa Miquel, Juan-Carlos García-Valdecasas, Miquel Navasa, Xavier Forns.   

Abstract

UNLABELLED: Significant liver fibrosis (F >or= 2) and portal hypertension (hepatic venous pressure gradient [HVPG] >or= 6 mmHg) at 1 year after liver transplantation (LT) identify patients with severe hepatitis C recurrence. We evaluated whether repeated liver stiffness measurements (LSM) following LT can discriminate between slow and rapid "fibrosers" (fibrosis stage F2-F4 at 1 year after LT). Eighty-four patients who had undergone LT and who were infected with hepatitis C virus (HCV) and 19 LT controls who were not infected with HCV underwent LSM at 3, 6, 9, and 12 months after LT. All HCV-infected patients underwent liver biopsy 12 months after LT (paired HVPG measurements in 74); 31 (37%) were rapid fibrosers. Median LSM (in kilopascal) at months 6, 9, and 12 were significantly higher in rapid fibrosers (9.9, 9.5, 12.1) than in slow fibrosers (6.9, 7.5, 6.6) (P < 0.01 all time points). The slope of liver stiffness progression (kPa x month) in rapid fibrosers (0.42) was significantly greater than in slow fibrosers (0.05) (P < 0.001), suggesting two different speeds of liver fibrosis progression. Figures were almost identical for patients with HVPG >or= 6 mmHg or HVPG < 6 mmHg at 1 year after LT. Multivariate analysis identified donor age, bilirubin level, and LSM as independent predictors of fibrosis progression and portal hypertension in the estimation group (n = 50) and were validated in a second group of 34 patients. The areas under the receiver operating characteristic curve that could identify rapid fibrosers and patients with portal hypertension as early as 6 months after LT were 0.83 and 0.87, respectively, in the estimation group and 0.75 and 0.80, respectively, in the validation group.
CONCLUSION: Early and repeated LSM following hepatitis C recurrence in combination with clinical variables discriminates between rapid and slow fibrosers after LT.

Entities:  

Mesh:

Year:  2010        PMID: 19839063     DOI: 10.1002/hep.23240

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

Review 1.  JSUM ultrasound elastography practice guidelines: liver.

Authors:  Masatoshi Kudo; Tsuyoshi Shiina; Fuminori Moriyasu; Hiroko Iijima; Ryosuke Tateishi; Norihisa Yada; Kenji Fujimoto; Hiroyasu Morikawa; Masashi Hirooka; Yasukiyo Sumino; Takashi Kumada
Journal:  J Med Ultrason (2001)       Date:  2013-08-16       Impact factor: 1.314

Review 2.  When and How to Treat HCV Infection with the New Antivirals before or after Liver Transplantation.

Authors:  Kerstin Herzer; Guido Gerken
Journal:  Visc Med       Date:  2016-06-20

3.  Non-invasive assessment of liver fibrosis in chronic hepatitis C.

Authors:  Laurent Castera
Journal:  Hepatol Int       Date:  2011-01-20       Impact factor: 6.047

Review 4.  Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation.

Authors:  Chrysoula Pipili; Evangelos Cholongitas
Journal:  World J Hepatol       Date:  2014-05-27

Review 5.  Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?

Authors:  Chrysoula Pipili; Evangelos Cholongitas
Journal:  World J Hepatol       Date:  2015-06-28

6.  Improving thermal ablation delineation with electrode vibration elastography using a bidirectional wave propagation assumption.

Authors:  Ryan J DeWall; Tomy Varghese
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2012-01       Impact factor: 2.725

Review 7.  Evolving challenges in hepatic fibrosis.

Authors:  Scott L Friedman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-29       Impact factor: 46.802

8.  Current status of novel antifibrotic therapies in patients with chronic liver disease.

Authors:  Michal Cohen-Naftaly; Scott L Friedman
Journal:  Therap Adv Gastroenterol       Date:  2011-11       Impact factor: 4.409

9.  Collagen crosslinking does not dictate stiffness in a transgenic mouse model of skeletal muscle fibrosis.

Authors:  Mark A Chapman; Rajeswari Pichika; Richard L Lieber
Journal:  J Biomech       Date:  2014-12-10       Impact factor: 2.712

10.  A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.

Authors:  James R Burton; Jacqueline G O'Leary; Elizabeth C Verna; Varun Saxena; Jennifer L Dodge; Richard T Stravitz; Joshua Levitsky; James F Trotter; Gregory T Everson; Robert S Brown; Norah A Terrault
Journal:  J Hepatol       Date:  2014-05-05       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.